ECSP20070185A - Análogos novedosos de glp-1 - Google Patents

Análogos novedosos de glp-1

Info

Publication number
ECSP20070185A
ECSP20070185A ECSENADI202070185A ECDI202070185A ECSP20070185A EC SP20070185 A ECSP20070185 A EC SP20070185A EC SENADI202070185 A ECSENADI202070185 A EC SENADI202070185A EC DI202070185 A ECDI202070185 A EC DI202070185A EC SP20070185 A ECSP20070185 A EC SP20070185A
Authority
EC
Ecuador
Prior art keywords
analogs
glp
action
new
present disclosure
Prior art date
Application number
ECSENADI202070185A
Other languages
English (en)
Inventor
Ravishankara Madavati Nagaraja
Kunal Pandya
Abhishek Tiwari
Rishit Mansukhlal Zalawadia
Nishith Chaturvedi
Vinod Sampatrao Burade
Dhiren Rameshchandra Joshi
Vipulkumar Shankarbhai Pa-Tel
Brijeshkumar Patel
Pradeep Dinesh Shahi
Krunal Harishbhai Soni
Rajamannar Thennati
Muthukumaran Natarajan
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of ECSP20070185A publication Critical patent/ECSP20070185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)

Abstract

La presente descripción se refiere a análogos novedosos del péptido similar al glucagón-1 (GLP-1) (7-37) que tienen una secuencia de aminoácidos con Leu o Ile en el C-terminal. Los nuevos análogos son potentes agonistas de GLP-1 con efecto adverso reducido y duración de la acción mejorada. La presente descripción se refiere además a derivados acilados de los nuevos análogos que tienen una potencia y duración de la acción mejoradas adicionalmente y son adecuados para la administración oral. Los análogos de la presente descripción pueden ser útiles en el tratamiento de la diabetes y la obesidad.
ECSENADI202070185A 2018-04-05 2020-11-05 Análogos novedosos de glp-1 ECSP20070185A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040474 2018-10-26
IN201821040468 2018-10-26

Publications (1)

Publication Number Publication Date
ECSP20070185A true ECSP20070185A (es) 2021-01-29

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202070185A ECSP20070185A (es) 2018-04-05 2020-11-05 Análogos novedosos de glp-1

Country Status (33)

Country Link
US (7) US11447535B2 (es)
EP (3) EP3774862B1 (es)
JP (2) JP7250814B2 (es)
KR (2) KR20250065720A (es)
CN (3) CN117964735A (es)
AU (3) AU2019247936C1 (es)
BR (1) BR112020020419A2 (es)
CA (1) CA3095988A1 (es)
CL (1) CL2020002574A1 (es)
CO (1) CO2020012425A2 (es)
CY (1) CY1125528T1 (es)
DK (2) DK3774862T3 (es)
EC (1) ECSP20070185A (es)
ES (2) ES2980707T3 (es)
FI (1) FI4122954T3 (es)
HR (2) HRP20221054T1 (es)
HU (2) HUE060135T2 (es)
IL (1) IL277483B1 (es)
JO (1) JOP20200251B1 (es)
LT (2) LT3774862T (es)
MX (2) MX2020010505A (es)
MY (1) MY202560A (es)
PE (1) PE20211417A1 (es)
PH (1) PH12020551591A1 (es)
PL (2) PL4122954T3 (es)
PT (2) PT4122954T (es)
RS (2) RS63523B1 (es)
SG (1) SG11202009467YA (es)
SI (2) SI4122954T1 (es)
SM (2) SMT202400241T1 (es)
UA (1) UA128210C2 (es)
WO (1) WO2019193576A1 (es)
ZA (1) ZA202306729B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63523B1 (sr) * 2018-04-05 2022-09-30 Sun Pharmaceutical Ind Ltd Novi glp-1 analozi
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
CN116171164A (zh) * 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
EP4429704A4 (en) 2021-11-10 2025-11-05 I2O Therapeutics Inc IONIC LIQUID COMPOSITIONS
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用
EP4724471A1 (en) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
CN121368489A (zh) 2023-06-20 2026-01-20 太阳医药工业有限公司 用于治疗代谢障碍的glp-1类似物
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法
WO2025163615A1 (en) 2024-01-31 2025-08-07 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP2002512175A (ja) 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69922043T2 (de) 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
MXPA04006679A (es) 2002-01-08 2004-11-10 Lilly Co Eli Analogos extendidos de peptido-1 de tipo glucagon.
CA2502118A1 (en) 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1 derivatives and transmicosal absorption preparations thereof
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
AU2004240630B2 (en) 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
JP5755398B2 (ja) * 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
EP1883419A4 (en) 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
BRPI0615573A2 (pt) 2005-09-08 2011-05-24 Tufts College análogos de glp-1 estabilizados
PL1767545T3 (pl) 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
BR112012027545B1 (pt) 2010-04-27 2020-09-24 Betta Pharmaceuticals Co., Ltd. Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
RU2602601C2 (ru) 2011-04-12 2016-11-20 Ново Нордиск А/С Дважды ацилированные производные glp-1
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2753642B8 (en) 2011-09-06 2017-12-13 Novo Nordisk A/S Glp-1 derivatives
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
ES2629735T3 (es) 2012-05-08 2017-08-14 Novo Nordisk A/S Derivados de GLP-1 doblemente acilados
KR20150023690A (ko) 2012-06-14 2015-03-05 사노피 엑센딘-4 펩타이드 유사체
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
KR20160021183A (ko) 2013-06-20 2016-02-24 노보 노르디스크 에이/에스 Glp-1 유도체 및 그것의 용도
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
WO2015000942A1 (en) 2013-07-04 2015-01-08 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
WO2015055801A1 (en) * 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
SG10201805039UA (en) 2013-12-13 2018-07-30 Medimmune Ltd Protease resistant peptides
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
WO2017035432A1 (en) 2015-08-26 2017-03-02 Robert Doyle Coagonists of glucagon-like peptide 1 receptor and neuropeptide y2 receptor
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
AU2017277594A1 (en) 2016-06-09 2019-02-07 Medimmune Limited Protease-resistant mono-lipidated peptides
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
WO2018178796A1 (en) 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
KR102829589B1 (ko) 2018-03-09 2025-07-04 프레제니우스 카비 입섬 에스. 알. 엘. 리라글루티드, 세마글루티드 및 glp-1의 화학-효소적 합성
RS63523B1 (sr) * 2018-04-05 2022-09-30 Sun Pharmaceutical Ind Ltd Novi glp-1 analozi

Also Published As

Publication number Publication date
EP3774862B1 (en) 2022-06-08
EP4364751A2 (en) 2024-05-08
AU2019247936A1 (en) 2020-10-15
BR112020020419A2 (pt) 2021-01-19
ES2925678T3 (es) 2022-10-19
SI3774862T1 (sl) 2022-10-28
KR20200141469A (ko) 2020-12-18
AU2019247936B2 (en) 2023-03-02
MX2020010505A (es) 2021-01-15
US12421289B2 (en) 2025-09-23
US20200362007A1 (en) 2020-11-19
CO2020012425A2 (es) 2020-12-21
JOP20200251B1 (ar) 2024-04-18
JP2021520346A (ja) 2021-08-19
AU2019247936C1 (en) 2023-06-15
LT4122954T (lt) 2024-06-25
DK4122954T3 (da) 2024-06-10
MX2024007688A (es) 2024-07-09
CA3095988A1 (en) 2019-10-10
US20210206823A1 (en) 2021-07-08
AU2023203430A1 (en) 2023-06-29
PT3774862T (pt) 2022-09-05
LT3774862T (lt) 2022-09-12
IL277483A (en) 2020-11-30
AU2023203430B2 (en) 2025-07-03
JOP20200251A1 (ar) 2020-10-04
ZA202306729B (en) 2024-03-27
RS63523B1 (sr) 2022-09-30
SMT202200352T1 (it) 2022-09-14
US11447535B2 (en) 2022-09-20
ES2980707T3 (es) 2024-10-02
HUE060135T2 (hu) 2023-02-28
CN112236444B (zh) 2025-09-19
PL3774862T3 (pl) 2022-10-03
HRP20221054T1 (hr) 2022-11-11
NZ768446A (en) 2025-10-31
PE20211417A1 (es) 2021-08-02
CY1125528T1 (el) 2026-02-25
RS65639B1 (sr) 2024-07-31
FI4122954T3 (fi) 2024-06-18
PL4122954T3 (pl) 2024-08-12
JP2023078367A (ja) 2023-06-06
US11242373B2 (en) 2022-02-08
CN120554480A (zh) 2025-08-29
CN112236444A (zh) 2021-01-15
SMT202400241T1 (it) 2024-07-09
US11866477B2 (en) 2024-01-09
CN117964735A (zh) 2024-05-03
IL277483B1 (en) 2026-01-01
HUE067499T2 (hu) 2024-10-28
EP4122954A1 (en) 2023-01-25
SI4122954T1 (sl) 2024-07-31
US20220402991A1 (en) 2022-12-22
KR20250065720A (ko) 2025-05-13
JP7250814B2 (ja) 2023-04-03
US11485766B2 (en) 2022-11-01
US11873328B2 (en) 2024-01-16
SG11202009467YA (en) 2020-10-29
US20220402992A1 (en) 2022-12-22
EP4364751A3 (en) 2024-06-26
US20240199718A1 (en) 2024-06-20
UA128210C2 (uk) 2024-05-08
CL2020002574A1 (es) 2021-06-04
US20240376175A1 (en) 2024-11-14
PT4122954T (pt) 2024-06-05
US20190309040A1 (en) 2019-10-10
DK3774862T3 (da) 2022-09-05
HRP20240749T1 (hr) 2024-09-13
PH12020551591A1 (en) 2021-08-16
MY202560A (en) 2024-05-08
KR102801994B1 (ko) 2025-04-30
AU2025242190A1 (en) 2025-10-23
WO2019193576A1 (en) 2019-10-10
EP3774862A1 (en) 2021-02-17
EP4122954B1 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
ECSP20070185A (es) Análogos novedosos de glp-1
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
MX2021000793A (es) Compuestos coagonistas de gip/glp1.
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
MX2020011007A (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado.
AR109274A2 (es) Composición que comprende uno o más fragmentos de péptido intestinal vasoactivo (vip) y su uso para la fabricación de un medicamento
PE20151770A1 (es) Compuesto peptidico
RU2011129784A (ru) Основанные на амидах пролекарства пептидов глюкагонового надсемейства
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
PE20100255A1 (es) Co-agonistas del receptor de glucagon/glp-1
PE20221518A1 (es) Analogos de incretina y sus usos
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
AR128464A1 (es) Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada
AR131483A1 (es) Agonista triple novedoso del receptor de glp-1 / gip / glucagón y una composición farmacéutica para prevenir o tratar la obesidad que lo comprende
TH2001005828A (th) Glp-1 อนาล็อกชนิดใหม่
EA202092017A1 (ru) Новые аналоги glp-1
AR119324A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
AR125905A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
NZ771617A (en) Glucagon derivatives
RU2011131714A (ru) Аналоги glp-1 и их использования
Fernández et al. The administration of hCG or GnRH induce the formation of accessory corpora lutea
NZ733649B2 (en) Glucagon derivatives